REGULATED PRESS RELEASE published on 10/27/2023 at 18:00, 1 year ago MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023
REGULATED PRESS RELEASE published on 10/23/2023 at 18:00, 1 year ago MEDESIS PHARMA PARTICIPATES IN THE 16th INTERNATIONAL CONGRESS “CLINICAL TRIALS ON ALZHEIMER DISEASE” (CTAD) IN BOSTON FROM OCTOBER 24 TO 27, 2023 AND PRESENTS A POSTER ON ITS CURRENT RESEARCH
REGULATED PRESS RELEASE published on 10/23/2023 at 18:00, 1 year ago MEDESIS PHARMA PARTICIPE AU 16ème CONGRÈS INTERNATIONAL « CLINICAL TRIALS ON ALZHEIMER DISEASE » (CTAD) À BOSTON DU 24 AU 27 OCTOBRE 2023 ET PRÉSENTE UN POSTER SUR SA RECHERCHE EN COURS
REGULATED PRESS RELEASE published on 10/17/2023 at 08:00, 1 year ago END OF ENROLLEMENT OF THE 68 PATIENTS IN MEDESIS PHARMA PHASE 2 CLINICAL STUDY OF NANOLITHIUM FOR THE TREATMENT OF ALZHEIMER’S DISEASE
REGULATED PRESS RELEASE published on 10/17/2023 at 08:00, 1 year ago FIN DU RECRUTEMENT DES 68 PATIENTS DANS L’ÉTUDE CLINIQUE DE PHASE 2 DE MEDESIS PHARMA SUR LE NANOLITHIUM POUR LE TRAITEMENT DE LA MALADIE D’ALZHEIMER
REGULATED PRESS RELEASE published on 10/13/2023 at 08:45, 1 year ago MEDESIS PHARMA : AUGMENTATION DES MOYENS ALLOUÉS AU CONTRAT DE LIQUIDITÉ CONCLU AVEC INVEST SECURITIES
REGULATED PRESS RELEASE published on 10/11/2023 at 18:00, 1 year ago MEDESIS PHARMA: PUBLICATION OF A SCIENTIFIC ARTICLE IN THE JOURNAL OF ALZHEIMER’S DISEASE ON THE USE OF LITHIUM FOR THE TREATMENT OF ALZHEIMER’S DISEASE
REGULATED PRESS RELEASE published on 10/11/2023 at 18:00, 1 year ago MEDESIS PHARMA : PUBLICATION D’UN ARTICLE SCIENTIFIQUE DANS LE JOURNAL OF ALZHEIMER’S DISEASE SUR L’UTILISATION DU LITHIUM POUR LE TRAITEMENT DE LA MALADIE D’ALZHEIMER
REGULATED PRESS RELEASE published on 10/03/2023 at 18:00, 1 year 1 month ago MEDESIS PHARMA RECEIVES APPROVAL FROM THE MONTPELLIER COMMERCIAL COURT TO OPEN A SAFEGUARD PROCEDURE
REGULATED PRESS RELEASE published on 10/03/2023 at 18:00, 1 year 1 month ago MEDESIS PHARMA OBTIENT UN ACCORD POUR L’OUVERTURE D’UNE PROCÉDURE DE SAUVEGARDE AUPRÈS DU TRIBUNAL DE COMMERCE DE MONTPELLIER
Published on 11/08/2024 at 10:00, 1 hour 19 minutes ago BluSky Carbon CEO Presents a Case for Climate Tech Optimism
Published on 11/08/2024 at 09:00, 2 hours 19 minutes ago Greene Tweed Awarded 'Excellence in International Trade' at the 2024 East Midlands Chamber Business Awards
Published on 11/08/2024 at 07:00, 4 hours 19 minutes ago Polaris Renewable Energy Announces Fixed Income Meetings
Published on 11/08/2024 at 03:00, 8 hours 19 minutes ago Alset AI Appoints Wall Street Veteran and Venture Executive as President
Published on 11/08/2024 at 01:25, 9 hours 54 minutes ago PetroFrontier Corp. Announces Execution of Definitive Agreements for $15.1 Million Funding Arrangement
Published on 11/08/2024 at 11:06, 13 minutes ago Original-Research: Knaus Tabbert AG (von First Berlin Equity Research GmbH): Kaufen
Published on 11/08/2024 at 11:00, 19 minutes ago BluSky Carbon CEO Presents a Case for ClimateTech Optimism
Published on 11/08/2024 at 10:43, 36 minutes ago Change of leadership at Hannover Re: Chief Executive Officer Jean-Jacques Henchoz hands over to Clemens Jungsthöfel on 1 April 2025
Published on 11/08/2024 at 10:40, 39 minutes ago EQS-Adhoc: Hannover Rück SE: Chief Executive Officer Jean-Jacques Henchoz hands over to Clemens Jungsthöfel on 1 April 2025
Published on 11/08/2024 at 08:00, 3 hours 19 minutes ago DAMARTEX / Droits de vote bruts et réels 31 octobre 2024
Published on 11/07/2024 at 19:00, 16 hours 19 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/07/2024 at 19:00, 16 hours 19 minutes ago ALTAREA : DECLARATION MENSUELLE DES OPERATIONS REALISEES PAR LA SOCIETE SUR SES PROPRES TITRES OCTOBRE 2024
Published on 11/07/2024 at 19:00, 16 hours 19 minutes ago ALTAREIT : DECLARATION MENSUELLE DES OPERATIONS REALISEES PAR LA SOCIETE SUR SES PROPRES TITRES OCTOBRE 2024
Published on 11/07/2024 at 19:00, 16 hours 19 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
